Zenith Drugs Limited
Book Built Issue IPO · NSE
- Price band
- ₹75 - ₹79
- Lot size
- 1,600 shares
- Issue amount
- ₹40.68 cr
- Total subscription
- 179.07×
- Opens
- 19 Feb 2024
- Closes
- 22 Feb 2024
- Allotment
- 23 Feb 2024
- Listing
- 27 Feb 2024
Offer at a glance
Issue overview
- Issue size
- 51,48,800 shares
- Face value
- ₹10 Per Equity Share
- Minimum investment
- ₹1,20,000
- Fresh issue
- ₹40.68 cr
- Offer for sale
- ₹0 cr
- Registrar
- Bigshare Services Private Limited
- Listing exchange
- NSE
- Maximum investment
- ₹1,26,400
- Issue type
- Book Built Issue IPO
- Shares before issue
- 1,20,00,000
- Shares after issue
- 1,71,48,800
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 1,600 | ₹1,26,400 |
| HNI | 2 | 3,200 | ₹2,52,800 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 6.79 | 724.41 |
| RETAIL | 11.88 | 1,646.4 |
| NIB | 5.09 | 1,884.46 |
Financial performance
Company financials
In Lakhs · Reported periods may include interim results.
Key performance indicators
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| EPS | 4.29 | 2.62 | 2.52 |
| ROE | 35.13 | 29.83 | 40.73 |
| ROCE | 37.29 | 30.08 | 36.52 |
| RONW | 29.88 | 25.96 | 33.84 |
| PRE IPO(PE) | 18.4 | 0 | 0 |
| POST IPO(PE) | 5.5 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Zenith Drugs Limited, founded in 2000, is a pharmaceutical company that manufactures and trades affordable, high-quality medicines, including various generic products. The company operates under WHO-GMP guidelines and holds an ISO 9001:2015 certification, reflecting its focus on quality. It offers a wide product range such as ORS powder, liquid orals, ointments, liquid externals, and capsules, with over 600 products approved by the Food & Drugs Administration and 325 currently in production. Zenith Drugs is expanding by setting up a new manufacturing facility in Muradpura, Depalpur, Indore, and it also exports its products to multiple regions including Central America, Africa, Southeast Asia, and South Asia. The company provides third-party manufacturing services to well-known pharmaceutical brands like Ajanta Pharma, Bio Medical Laboratories, and Zest Pharma, and as of March 31, 2023, it employs 89 people, including both payroll and contract staff.
Strengths
- Experienced Leadership: The company is guided by seasoned promoters and a skilled management team, ensuring strong leadership and strategic growth.
- Cost Efficiency: A focus on cost-effective operations helps maximize resource use, boosting profitability and competitiveness.
- Innovation & Development: Strong formulation and development capabilities allow the company to innovate and adapt to market trends, setting it apart from competitors.
- Regulatory Compliance: Strict adherence to regulations ensures smooth operations, reduces risks, and strengthens the company’s reputation.
- Global Presence: A broad international market reach helps diversify revenue streams and reduces reliance on any single region.
Risk factors
- Restrictive Financing Conditions: The company must get lender approval for financial decisions like borrowing or restructuring, which may limit flexibility in operations.
- Raw Material & Supplier Dependency: Relying on key suppliers without long-term contracts poses a risk—any shortages or price hikes could impact production and profitability.
- Manufacturing & Quality Risks: Any issues in production or quality control could disrupt operations, harm the company’s reputation, and lead to potential legal challenges.
- Rising Competition: Failure to keep up with increasing competition could result in lower market share and reduced profitability.
- Customer Payment Delays: Late or missed payments from customers could strain cash flow, affecting daily operations and financial stability.
Promoters
Mr. Sandeep Bhardwaj
Mr. Bhupesh Soni
Mr. Ajay Singh Dassundi
Registrar & documents
Lead manager
Gretex Corporate Services Limited
Registrar & contacts
Bigshare Services Private Limited
[email protected]Official registrar portal ↗Check allotment status on registrar →Registered office
K. No. 72 / 5, Village Muradpura NA Depalpur, Indore-453001
+91 8435501867
[email protected]Company website ↗Frequently Asked Questions
What is Zenith Drugs IPO GMP today?
As of today, Zenith Drugs IPO Grey Market Premium (GMP) is reported at +₹35 per share. Based on the upper price band of ₹79, the estimated listing price is ₹114 (+44.3% expected listing gain). Please note that GMP is an unofficial market estimate for sentiment tracking and does not guarantee the actual listing price.
What is the lot size and minimum investment for Zenith Drugs IPO?
The minimum bid lot size for Zenith Drugs IPO is 1,600 shares. At the cut-off price of ₹79 per share, retail investors need a minimum application amount of ₹1,26,400 per lot. Retail applicants can apply for a maximum of 1 lots (up to ₹2,00,000).
When will Zenith Drugs IPO allotment status be announced?
The allotment status for Zenith Drugs IPO is scheduled to be finalized on 23 Feb 2024. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Bigshare Services Private Limited's official portal or via BSE/NSE allotment portals.
How can I check Zenith Drugs IPO allotment status online by PAN?
To check Zenith Drugs IPO allotment status: 1) Visit the registrar portal (Bigshare Services Private Limited) or the BSE IPO allotment page. 2) Select 'Zenith Drugs Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.
Explore More IPO Analysis & Live Tools
Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.